Ignite Creation Date:
2024-05-05 @ 11:35 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00085813
Status:
COMPLETED
Last Update Posted:
2010-10-04
First Post:
2004-06-14
Brief Title:
Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Phase II Open-Label Study of Ispinesib in Subjects With Locally Advanced or Metastatic Platinum-Refractory or Platinum-Relapsed Non-Small Cell Lung Cancer NSCLC
Status:
COMPLETED
Status Verified Date:
2010-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study was designed to determine how effective and safe Ispinesib is in treating locally advanced or metastatic Non-small Cell Lung cancer in patients who have received a platinum-based chemotherapy and whose disease continues to progress Treatment involves a 1-hr treatment given intravenously IV repeated once every 21 days A patient may continue treatment as long as they are benefiting from the treatment Blood samples will be taken at specific times over 24 hr period to measure the amount of drug in your body at specific times after the drug is given Blood samples will also be taken for routine lab tests such as complete blood counts and clinical chemistries Physical exams will be performed before each treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None